Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11 -Mutant Non-Small-Cell Lung Cancer.
Abdul Rafeh NaqashCharalampos S FloudasEtan AberAsaf MaozAmin H NassarElio AdibKhalil ChoucairJoanne XiuYasmine BacaBiagio RicciutiJoao M Victor AlessiMark M AwadChul KimJulia JuddLuis E RaezGilberto de Lima LopesJorge J NievaHossein BorghaeiNaoko TakebePatrick C MaBalazs HalmosDavid J KwiatkowskiStephen V LiuHirva MamdaniPublished in: JCO precision oncology (2024)
comutation is a distinct subgroup with an immunologically active TIME and metabolic reprogramming. These properties should be exploited to guide patient selection for novel ICI-based combination approaches.